Anzeige
Mehr »
Login
Freitag, 18.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
5 Millionen Unzen und steigend: NexGold Mining's unerschlossene Goldstraße
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DKLR | ISIN: US14986C1027 | Ticker-Symbol: B6JA
Frankfurt
17.10.24
08:03 Uhr
0,985 Euro
-0,025
-2,48 %
Branche
Elektrotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CBAK ENERGY TECHNOLOGY INC Chart 1 Jahr
5-Tage-Chart
CBAK ENERGY TECHNOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9700,98017.10.
0,9501,01017.10.
PR Newswire
107 Leser
Artikel bewerten:
(0)

CBAK Energy Technology, Inc.: CBAK Energy Unveils Breakthrough in Fast-Charging Technology with Enhanced Model 32140 Battery, Achieving Full Charge in Just 35 Minutes

DALIAN, China, June 4, 2024 /PRNewswire/ -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy," or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider in China, today announced a significant technological advancement with its model 32140 battery, a large cylindrical lithium-ion battery mass produced at its Nanjing facility.

The Company has successfully upgraded and innovated the battery structure, adopting a brand-new design based on the original battery cell structure. This upgrade has enabled the model 32140 large cylindrical battery to increase its fast-charging capability from the original 0.8C fast charging rate and a full charge in 75 minutes to a 1.8C fast charging rate and a full charge within just 35 minutes, achieving 1.25 times faster charging speed. Additionally, the battery's cycle life under high-current charge and discharge has doubled, enhancing the overall durability and efficiency of the product. CBAK Energy has filed a patent application for this novel technology with the relevant authorities in China, anticipating imminent approval.

The model 32140 large cylindrical battery is currently one of the most mature large cylindrical battery solutions on the market. Since commencing mass production in the second half of 2021, it has undergone more than two years of market validation, leading to a significant increase in sales. With the integration of innovative technologies facilitating the product iterations and upgrades, alongside the addition of new clients, the Company anticipates a substantial increase in sales of this product in key markets such as India and China this year.

Yunfei Li, Chairman and Chief Executive Officer of CBAK Energy, commented: "We are thrilled to announce this meaningful advance in our model 32140 battery. The enhanced fast-charging capability underscores our commitment to innovation and meeting the evolving needs of our clients. This breakthrough not only sets a new benchmark in the industry but also reinforces CBAK Energy's position as a leader in battery technology. We look forward to continuing to drive progress and deliver superior energy solutions."

About CBAK Energy

CBAK Energy Technology, Inc. (NASDAQ: CBAT) is a leading high-tech enterprise in China engaged in the development, manufacturing, and sales of new energy high power lithium and sodium batteries, as well as the production of raw materials for use in manufacturing high power lithium batteries. The applications of the Company's products and solutions include electric vehicles, light electric vehicles, energy storage and other high-power applications. In January 2006, CBAK Energy became the first lithium battery manufacturer in China listed on the Nasdaq Stock Market. CBAK Energy has multiple operating subsidiaries in Dalian, Nanjing, Shaoxing and Shangqiu, as well as a large-scale R&D and production base in Dalian.

For more information, please visit ir.cbak.com.cn.

Safe Harbor Statement

This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding the Company's future results of operations and financial position, strategy, plans, and expectations for future operations, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. The Company has attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Actual results of the Company may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements.

The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

For further inquiries, please contact:

In China:

CBAK Energy Technology, Inc.
Investor Relations Department
Phone: +86-18675423231
Email: [email protected]

Piacente Financial Communications
Ms. Hui Fan
Tel: +86-10-6508-0677
Email: [email protected]

In the United States:

Piacente Financial Communications
Ms. Brandi Piacente
Tel: +1-212-481-2050
Email: [email protected]

SOURCE CBAK Energy Technology, Inc.

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.